Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Doctor Jeffrey Cummings is world-renowned in the field of Alzheimer's research and he leads UNLV's Center for Transformative Neuroscience.

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.

Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...